Escape Bio website homepage

'Sor­ry, Es­cape Bio closed': A neu­rode­gen­er­a­tive up­start ex­its bid to ri­val Bio­gen-De­nali

A neu­rode­gen­er­a­tive dis­ease-fo­cused biotech that was at­tempt­ing to go up against the bil­lion-dol­lar pair­ing of Bio­gen and De­nali has shut­tered, End­points News has learned.

Es­cape Bio had built a pipeline of three small mol­e­cules for pa­tients with forms of Nie­mann-Pick Type C, Parkin­son’s and Alzheimer’s and wooed a who’s who of biotech in­vestors. Bankrollers in­clud­ed the VC arms of J&J and No­var­tis, Welling­ton Cap­i­tal Man­age­ment, Or­biMed, No­vo Hold­ings, Sut­ter Hill Ven­tures, Sur­vey­or Cap­i­tal and more than half a dozen oth­ers.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.